Halozyme Therapeutics HALO
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
HALO at a glance
Shares of Halozyme Therapeutics are down 1.82% at $91.35. The company is worth $10.41B, number 1380 out of 3753 on our list.
Over the past 52 weeks it has traded between $61.23 and $134.00, so it sits 31.8% below the top of that range. Holders are ahead 29.9% over twelve months, but down 15.9% across the last three months.
Price is below the 50-day average ($113.21) but above the 200-day ($85.89); RSI is 20, which some call oversold, and the last 30 sessions moved at roughly 60% annualized volatility.
In the quarter ended Sep 2026 the company brought in $492.97M of revenue, up 39.2% from a year earlier, with $247.05M of net profit (a 26.9% margin).
The stock changes hands at 22.8 times trailing earnings, 8% above its five-year average of 21.1. The median for its industry group is 17.1.
5 analysts follow the stock and the average call is "buy". The mean target, $125.60, sits 37.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Key statistics
Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
5 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
Six-factor research snapshot
Overall percentile: 93.8 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.
| Factor | Percentile |
|---|---|
| Valuation | 40.3 |
| Growth | 82.4 |
| Profitability | 98.3 |
| Momentum | 69.1 |
| Financial health | 58.8 |
| Analyst view | 61.9 |
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $125.60, 37.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $92.48, so shares trade 1.2% below that estimate. On earnings multiple, it sits in the 65th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -18.6% | Bearish |
| Price vs 50-day average | -19.3% | Bearish |
| Price vs 200-day average | +6.4% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 20.0 | Neutral |
| MACD (12,26,9) | -6.81 | Bearish |
| Bollinger band position | 17% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
How HALO ranks on BeStock
Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 22.8x earnings, HALO looks expensive against the market, and trades 34% above the 17.1x median among Biotechnology names. The two comparisons do not always agree.
BeStock Momentum
HALO is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on HALO.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Community Sentiment on HALO
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
HALO stock: common questions
How is Halozyme Therapeutics stock doing today?
$91.35 is the latest print for HALO, a move of -1.82% against yesterday's close of $93.04. Today's low and high so far: $90.79 and $93.64.
How big is Halozyme Therapeutics?
Equity value comes to $10.41B at the current price. By that measure it is number 1380 of the 3753 names in our coverage.
Is HALO expensive on earnings?
Buyers pay 22.8 times the last twelve months of profit (EPS $2.56). Averaged over five years the multiple has been 21.1, and today's level ranks in the 65th percentile of its own history.
Where does HALO sit in its 52-week range?
The year's floor is $61.23 and the ceiling $134.00. Shares are 31.8% away from that ceiling.
Does HALO send cash back through a dividend?
Our data shows no dividend paid by Halozyme Therapeutics over the trailing twelve months.
Do Wall Street analysts like HALO?
Of 5 analysts, 80% say buy, 20% hold and 0% sell. Price targets average $125.60, with the most cautious at $109.00 and the most optimistic at $149.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.